OndansetronPhase 4EffOndNCT03629522
Effects of Ondansetron on Hemodynamics in Cesarean Section Under Spinal Anesthesia
A Phase 4 study testing Ondansetron 8Mg/4mL Injection in people with Ondansetron and Cesarean Section, run by University Hospital, Mahdia at 2 sites in Tunisia.
Trial summary
BACKGROUND: Spinal anesthesia (SA) induced maternal hypotension is the most frequent and troublesome complication in cesarean section (CS), compromising both maternal and neonatal well-being. Many strategies have been used to prevent its occurrence but no single technique has been confirmed to be completely effective. Read more about this study
- Who is it for?
- Ages 20 to 40 years, women only
- Conditions the study is for
- Ondansetron, Cesarean Section, Spinal Anesthesia
- What is being tested?
- Ondansetron 8Mg/4mL Injection
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 100 participants
- Where
- 2 sitesTunisia
- Study dates
- 1 Aug 2017to 30 Dec 2017
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 40 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Parturients eligible for the present study are women who:
- are scheduled for elective cesarean section under spinal anesthesia
- aged between 20 to 40 years
- are with an American Society of Anesthesiologist (ASA) physical status of I-II
- are with a normal liver and renal function and fetal screening, and with no medical history of heart disease.
- are with a single fetus.
Who cannot join
- Refusal to participate.
- Contraindication to spinal anesthesia
- Age <20 or >40 years.
- Obesity (body mass index (BMI) at term >35 kg/m2).
- History of hypersensitivity to study's drugs.
- History of long QT syndrome
Show all 13Show fewer
- Hypertensive disorders of pregnancy.
- Women receiving selective serotonin reuptake inhibitors or migraine medications.
- Urgent cesarean section.
- Multiple pregnancies.
- Failure of spinal anesthesia.
- Conversion to general anesthesia.
- The occurrence of an anesthetic or surgical complication.
Trial locations and contacts
2 sites in 1 country.
Tunisia2 sites
Mahdia University Hospital
Mahdia, 5100
Ministry of Health
Tunis, 1002
About this study
Official title: Effects on Ondansetron on Maternal Hemodynamics After Cesarean Section Under Spinal Anesthesia: a Randomized Controlled Trial
BACKGROUND:
Spinal anesthesia (SA) induced maternal hypotension is the most frequent and troublesome complication in cesarean section (CS), compromising both maternal and neonatal well-being. Many strategies have been used to prevent its occurrence but no single technique has been confirmed to be completely effective. the investigators hypothesized that ondansetron, a serotonin-receptor-antagonist, could have beneficial effects on maternal hemodynamics during CS under SA.
Read more
METHODS:
In this prospective double-blind placebo-controlled study, one hundred healthy parturients were randomized to receive either 8 mg of intravenous ondansetron (group O) or the same volume of saline (group S), 5 minutes prior to the induction of SA. All women received a coloading volume of 500 ml of saline. Maternal hemodynamics: blood pressure, heart rate and cardiac output (CO) were measured with a non-invasive device based on pulse wave transit time: the esCCO device Nihon Kohden hemodynamic monitor. Ephedrine was administered to treat hypotension (systolic blood pressure less than 80% of baseline).
Read the detailed description
- Type of the study: After institutional ethical committee approval, we conducted a prospective double-blind, placebo-controlled, randomized study, at the department of anesthesiology of the Mahdia's university hospital, from August to November 2017.
- Inclusion criteria: Parturients eligible for the present study are women who: are scheduled for elective cesarean section under spinal anesthesia. aged between 20 to 40 years. are with an American Society of Anesthesiologist (ASA) physical status of I-II are with a normal liver and renal function and fetal screening, and with no medical history of heart disease. are with a single fetus.
- Protocol description:
3.1. Pre-operative time: A pre-anesthetic consultation, carried out at least 48 hours before the surgical procedure, made it possible to define eligible women for our study, to inform the parturients about the nature and the progress of the protocol and to collect their consent. Women were fasted for 6 hours before surgery and did not receive any premedication. In the morning of the intervention, a preoperative visit allowed us to check the application of instructions and the absence of intercurrent event.
3.2. per-operative time:
Randomization was performed at the entrance to the operating room after verification of the inclusion and exclusion criteria. All participants were randomly assigned to one of two groups according to a randomization table.
In the operating room, baseline values of noninvasive blood pressure (BP), electrocardiogram (ECG), and pulse oximetry (SPO2) were recorded using a Nihon Kohden monitor which also allowed a continuous non-invasive estimation of cardiac output (esCCO), based on pulse wave transit time (PWTT) which is automatically computed from pulse Oximetry waveform and electrocardiogram signals. After inputting the date of birth, sex, weight and height, the monitor was calibrated by the heart rate, pulse pressure, and PWTT.
Peripheral venous access was secured with an 18-gauge canula. An anesthesia nurse ; not included in the analysis ;verified the allocation and prepared the appropriate dose of Ondansetron (8 mg) with 0.9% saline solution to a total volume of 10 ml or a placebo of 0.9% saline solution10 ml. The syringes had no identifying markers indicating group allocation. The nurse injected the contents of the syringe intravenously over 60 s, 5 min before the lumbar puncture was performed. The anesthetist caring for the woman was blinded to group allocation.
Spinal anesthesia was induced in the sitting position at the L3-4 or L4-5 interspace, with a 25-gauge spinal needle pencil point. We administered 10 mg of 0.5% hyperbaric Bupivacaine, with 5ɤof Sufentanil and 100ɤof morphine. After injection, patients were immediately placed supine with 15 degrees left tilt. All women were rapidly coloaded with 500 ml of 0.9% saline solution.
Hemodynamic data were recorded at 2-min interval in the first 15-min and then every 5-min until the end of the procedure.
Sensory block height level was checked by assessing the perception of coldness using an alcohol swab, and motor block using Bromage scale.
Supplemental oxygen was administered via nasal canula at 2L/min. Maintenance fluids (10 ml/kg in the first one hour and 5ml/kg in the subsequent hours) were given at room temperature. Oxytocin was given following delivery of the fetus (5 IU directly and 10 IU in 250 ml of Glucose solution 5%). Antibioprophylaxis using 2g of Cefazolin was administered intravenously, in case of allergy, we used Clindamycin.
Neonatal Apgar score was noted at 1 and 5min after delivery.
Hypotension was defined as a decrease in systolic blood pressure (SBP)> 25% of baseline, and severe hypotension was defined as SBP< 80 mmHg. Treatment was initiated with intravenous Ephedrine 9 mg. More bolus of Ephedrine can be required.
Bradycardia, defined as a decrease in heart rate (HR) to less than 50 beats/min, was treated with intravenous atropine 0.5 mg.
Tachycardia was defined as HR >120 beats/min. Low flow was defined as a decrease in cardiac output (CO) > 15% from baseline.
3.3. Post-operative time:
After surgery, all parturients were transferred to the post-intervention monitoring room.
Standard monitoring of all parturients systematically included heart rate (HR), non invasive blood pressure (NIBP), respiratory frequency (RR), uterine globe tonus, bleeding, diuresis and temperature.
A glucose solution 5 % infusion enriched with electrolytes and comprising 20 IU of Oxytocin was instituted at a rate of 2 liters to 3l/24 h depending on the weight of the parturient.
The protocol of postoperative analgesia is ensured by the administration of Paracetamol in slow intravenous infusion at the dose of 1gevery 6 hours and Nefopam at the dose of 20 mg in slow infusion of 30 min every 8 hours. The postoperative prescription included also for all parturients Enoxaparin-based thrombophylaxis for 7 days.
- Conditions
- Ondansetron, Cesarean Section, Spinal Anesthesia, Hemodynamics
- Being tested
- Ondansetron 8Mg/4mL Injection
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ondansetron 8Mg/4mL InjectionDrug
Also called OD-C/S
investigators administrated intravenously Ondansetron 8 mg 5 minutes before spinal anesthesia.
| Study group | Role | What they receive |
|---|---|---|
| ondansetron group | Active comparator | Ondansetron 8Mg/4mL Injection: administration of a bolus of 8 mg intravenous Ondansetron diluted in 10 ml of saline solution (0,09%) 5 minutes before spinal anesthesia Receives: Drug: Ondansetron 8Mg/4mL Injection |
| control group | Placebo comparator | administration of 10 ml of saline solution (0,09%) 5 minutes before spinal anesthesia Receives: Drug: Ondansetron 8Mg/4mL Injection |
What is being measured
The primary outcome is the main question the study is designed to answer.
hypotension
decrease of systolic blood pressue with more than 25% from baseline values
Measured: 5 min after spinal anesthésia
Secondary outcomes (2)
escco
decrease of cardiac output (contious non invasive estimation of cardiac output based on pulse wave transit time) with more than 15% from baseline values
Measured: 5 min after spinal anesthésia
ephedrine consumption
ephedrine dose used in perioperative time
Measured: during 2 hours of anesthetic time
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Aug 2018
- Study start1 Aug 2017
- Primary completion30 Nov 2017
- Study completion30 Dec 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for OndansetronStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Ondansetron group (group O): 8mg(10 ml) of Ondansetron administrated 5 minutes before spinal anesthesia control group (group C): saline solution 0,9%(10ml)
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Outcomes assessor
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Mahdia
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Majdoub Ali MD, University Hospital, Mahdia
- Investigators
- bechir haddad, professor, Study director, tunisian Ministry of Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03629522
- Sponsor's protocol ID
- C/SOP2018
- Acronym
- EffOnd
- Status last verified
- Aug 2018
- First submitted
- 24 Apr 2018
- Last updated
- 14 Aug 2018
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Aug 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects on Ondansetron on Maternal Hemodynamics After Cesarean Section Under Spinal Anesthesia: a Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT03629522
- Acronym / sponsor ID
- EffOnd / C/SOP2018
- Conditions
- Ondansetron, Cesarean Section, Spinal Anesthesia, Hemodynamics
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- University Hospital, MahdiaUniversity, hospital or other
- Study start
- 1 Aug 2017 (actual)
- Primary completion
- 30 Nov 2017 (actual)
- Study completion
- 30 Dec 2017 (actual)
- First posted
- 14 Aug 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
BACKGROUND:
Spinal anesthesia (SA) induced maternal hypotension is the most frequent and troublesome complication in cesarean section (CS), compromising both maternal and neonatal well-being. Many strategies have been used to prevent its occurrence but no single technique has been confirmed to be completely effective. the investigators hypothesized that ondansetron, a serotonin-receptor-antagonist, could have beneficial effects on maternal hemodynamics during CS under SA.
METHODS:
In this prospective double-blind placebo-controlled study, one hundred healthy parturients were randomized to receive either 8 mg of intravenous ondansetron (group O) or the same volume of saline (group S), 5 minutes prior to the induction of SA. All women received a coloading volume of 500 ml of saline. Maternal hemodynamics: blood pressure, heart rate and cardiac output (CO) were measured with a non-invasive device based on pulse wave transit time: the esCCO device Nihon Kohden hemodynamic monitor. Ephedrine was administered to treat hypotension (systolic blood pressure less than 80% of baseline).
Detailed description
- Type of the study: After institutional ethical committee approval, we conducted a prospective double-blind, placebo-controlled, randomized study, at the department of anesthesiology of the Mahdia's university hospital, from August to November 2017.
- Inclusion criteria: Parturients eligible for the present study are women who: are scheduled for elective cesarean section under spinal anesthesia. aged between 20 to 40 years. are with an American Society of Anesthesiologist (ASA) physical status of I-II are with a normal liver and renal function and fetal screening, and with no medical history of heart disease. are with a single fetus.
- Protocol description:
3.1. Pre-operative time: A pre-anesthetic consultation, carried out at least 48 hours before the surgical procedure, made it possible to define eligible women for our study, to inform the parturients about the nature and the progress of the protocol and to collect their consent. Women were fasted for 6 hours before surgery and did not receive any premedication. In the morning of the intervention, a preoperative visit allowed us to check the application of instructions and the absence of intercurrent event.
3.2. per-operative time:
Randomization was performed at the entrance to the operating room after verification of the inclusion and exclusion criteria. All participants were randomly assigned to one of two groups according to a randomization table.
In the operating room, baseline values of noninvasive blood pressure (BP), electrocardiogram (ECG), and pulse oximetry (SPO2) were recorded using a Nihon Kohden monitor which also allowed a continuous non-invasive estimation of cardiac output (esCCO), based on pulse wave transit time (PWTT) which is automatically computed from pulse Oximetry waveform and electrocardiogram signals. After inputting the date of birth, sex, weight and height, the monitor was calibrated by the heart rate, pulse pressure, and PWTT.
Peripheral venous access was secured with an 18-gauge canula. An anesthesia nurse ; not included in the analysis ;verified the allocation and prepared the appropriate dose of Ondansetron (8 mg) with 0.9% saline solution to a total volume of 10 ml or a placebo of 0.9% saline solution10 ml. The syringes had no identifying markers indicating group allocation. The nurse injected the contents of the syringe intravenously over 60 s, 5 min before the lumbar puncture was performed. The anesthetist caring for the woman was blinded to group allocation.
Spinal anesthesia was induced in the sitting position at the L3-4 or L4-5 interspace, with a 25-gauge spinal needle pencil point. We administered 10 mg of 0.5% hyperbaric Bupivacaine, with 5ɤof Sufentanil and 100ɤof morphine. After injection, patients were immediately placed supine with 15 degrees left tilt. All women were rapidly coloaded with 500 ml of 0.9% saline solution.
Hemodynamic data were recorded at 2-min interval in the first 15-min and then every 5-min until the end of the procedure.
Sensory block height level was checked by assessing the perception of coldness using an alcohol swab, and motor block using Bromage scale.
Supplemental oxygen was administered via nasal canula at 2L/min. Maintenance fluids (10 ml/kg in the first one hour and 5ml/kg in the subsequent hours) were given at room temperature. Oxytocin was given following delivery of the fetus (5 IU directly and 10 IU in 250 ml of Glucose solution 5%). Antibioprophylaxis using 2g of Cefazolin was administered intravenously, in case of allergy, we used Clindamycin.
Neonatal Apgar score was noted at 1 and 5min after delivery.
Hypotension was defined as a decrease in systolic blood pressure (SBP)> 25% of baseline, and severe hypotension was defined as SBP< 80 mmHg. Treatment was initiated with intravenous Ephedrine 9 mg. More bolus of Ephedrine can be required.
Bradycardia, defined as a decrease in heart rate (HR) to less than 50 beats/min, was treated with intravenous atropine 0.5 mg.
Tachycardia was defined as HR >120 beats/min. Low flow was defined as a decrease in cardiac output (CO) > 15% from baseline.
3.3. Post-operative time:
After surgery, all parturients were transferred to the post-intervention monitoring room.
Standard monitoring of all parturients systematically included heart rate (HR), non invasive blood pressure (NIBP), respiratory frequency (RR), uterine globe tonus, bleeding, diuresis and temperature.
A glucose solution 5 % infusion enriched with electrolytes and comprising 20 IU of Oxytocin was instituted at a rate of 2 liters to 3l/24 h depending on the weight of the parturient.
The protocol of postoperative analgesia is ensured by the administration of Paracetamol in slow intravenous infusion at the dose of 1gevery 6 hours and Nefopam at the dose of 20 mg in slow infusion of 30 min every 8 hours. The postoperative prescription included also for all parturients Enoxaparin-based thrombophylaxis for 7 days.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, outcomes assessor)
- Number of arms
- 2
- Model description
- Ondansetron group (group O): 8mg(10 ml) of Ondansetron administrated 5 minutes before spinal anesthesia control group (group C): saline solution 0,9%(10ml)
| Arm | Type | Receives |
|---|---|---|
| ondansetron group | Active comparator | Drug: Ondansetron 8Mg/4mL InjectionOndansetron 8Mg/4mL Injection: administration of a bolus of 8 mg intravenous Ondansetron diluted in 10 ml of saline solution (0,09%) 5 minutes before spinal anesthesia |
| control group | Placebo comparator | Drug: Ondansetron 8Mg/4mL Injectionadministration of 10 ml of saline solution (0,09%) 5 minutes before spinal anesthesia |
Who may qualify
- Ages
- 20 to 40 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- are scheduled for elective cesarean section under spinal anesthesia
- aged between 20 to 40 years
- are with an American Society of Anesthesiologist (ASA) physical status of I-II
- are with a normal liver and renal function and fetal screening, and with no medical history of heart disease.
- are with a single fetus.
Key exclusion criteria (13 listed)
- Refusal to participate.
- Contraindication to spinal anesthesia
- Age <20 or >40 years.
- Obesity (body mass index (BMI) at term >35 kg/m2).
- History of hypersensitivity to study's drugs.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ondansetron 8Mg/4mL InjectionAlso: OD-C/Sinvestigators administrated intravenously Ondansetron 8 mg 5 minutes before spinal anesthesia. | Drug | control group, ondansetron group |
Primary outcome
hypotension
Time frame: 5 min after spinal anesthésia
decrease of systolic blood pressue with more than 25% from baseline values
2 secondary outcomes
escco
Time frame: 5 min after spinal anesthésia
ephedrine consumption
Time frame: during 2 hours of anesthetic time
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Aug 2018.
- Individual participant dataSharing planned: No
Related trials for Ondansetron
RecruitingPhase 4
BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron
Nausea With Vomiting Chemotherapy-Induced
Not yet recruitingPhase 4
Effect of Ondansetron on the Incidence of Spinal Anaesthesia-Induced Hypotension in Elderly Patients Undergoing Fracture Hip Surgery
Spinal Anaesthesia Induced Hypotension
Not yet recruitingPhase 4
Effects of Ondansetron Timing During Spinal Anesthesia for Urologic Surgery
Spinal Anesthesia-Induced Hypotension, Cerebral Oxygenation
Not yet recruitingPhase 2
Ondansetron to Prevent Oral Rehydration Failure in Children With Cholera
Cholera (Disorder)
RecruitingPhase 1
A Study to Compare the Bioavailability of Ondansetron Following Nasal (NS003) and IV Administration in Healthy Adults
Chemotherapy-Induced Nausea and Vomiting (CINV), Radiotherapy-induced Nausea and Vomiting (RINV)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
bechir haddad, professor study director
tunisian Ministry of Health
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Ondansetron 8Mg/4mL Injection in people with Ondansetron and Cesarean Section, run by University Hospital, Mahdia at 2 sites in Tunisia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Aug 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Tunisia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
hypotension (time frame: 5 min after spinal anesthésia). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2018.